vs
Side-by-side financial comparison of agilon health, inc. (AGL) and Organon & Co. (OGN). Click either name above to swap in a different company.
agilon health, inc. is the larger business by last-quarter revenue ($1.6B vs $1.5B, roughly 1.0× Organon & Co.). agilon health, inc. runs the higher net margin — -12.0% vs -13.6%, a 1.6% gap on every dollar of revenue. On growth, agilon health, inc. posted the faster year-over-year revenue change (3.1% vs -5.3%). Organon & Co. produced more free cash flow last quarter ($96.0M vs $-23.5M). Over the past eight quarters, agilon health, inc.'s revenue compounded faster (-1.1% CAGR vs -3.6%).
agilon health, inc. is a U.S.-based healthcare company partnering with primary care providers to deliver value-based care solutions mainly for senior Medicare beneficiaries. It offers administrative support, clinical tools and risk management frameworks to help physicians improve patient outcomes and cut care costs, operating across over 20 U.S. states.
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy (HRT), and anesthesia. Organon produces all its products outside of the United States but receives a third of its revenue from the United States.
AGL vs OGN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.6B | $1.5B |
| Net Profit | $-188.9M | $-205.0M |
| Gross Margin | — | 49.2% |
| Operating Margin | -12.3% | -9.8% |
| Net Margin | -12.0% | -13.6% |
| Revenue YoY | 3.1% | -5.3% |
| Net Profit YoY | -78.5% | -288.1% |
| EPS (diluted) | — | $-0.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.6B | $1.5B | ||
| Q3 25 | $1.4B | $1.6B | ||
| Q2 25 | $1.4B | $1.6B | ||
| Q1 25 | $1.5B | $1.5B | ||
| Q4 24 | $1.5B | $1.6B | ||
| Q3 24 | $1.5B | $1.6B | ||
| Q2 24 | $1.5B | $1.6B | ||
| Q1 24 | $1.6B | $1.6B |
| Q4 25 | $-188.9M | $-205.0M | ||
| Q3 25 | $-110.2M | $160.0M | ||
| Q2 25 | $-104.4M | $145.0M | ||
| Q1 25 | $12.1M | $87.0M | ||
| Q4 24 | $-105.8M | $109.0M | ||
| Q3 24 | $-117.6M | $359.0M | ||
| Q2 24 | $-30.7M | $195.0M | ||
| Q1 24 | $-6.1M | $201.0M |
| Q4 25 | — | 49.2% | ||
| Q3 25 | — | 53.5% | ||
| Q2 25 | — | 54.8% | ||
| Q1 25 | — | 55.6% | ||
| Q4 24 | — | 56.3% | ||
| Q3 24 | — | 58.3% | ||
| Q2 24 | — | 58.4% | ||
| Q1 24 | — | 59.0% |
| Q4 25 | -12.3% | -9.8% | ||
| Q3 25 | -9.1% | 15.2% | ||
| Q2 25 | -8.3% | 14.4% | ||
| Q1 25 | -1.4% | 6.7% | ||
| Q4 24 | -7.1% | 8.1% | ||
| Q3 24 | -9.2% | 13.1% | ||
| Q2 24 | -2.9% | 14.6% | ||
| Q1 24 | -0.4% | 14.5% |
| Q4 25 | -12.0% | -13.6% | ||
| Q3 25 | -7.7% | 10.0% | ||
| Q2 25 | -7.5% | 9.1% | ||
| Q1 25 | 0.8% | 5.8% | ||
| Q4 24 | -6.9% | 6.8% | ||
| Q3 24 | -8.1% | 22.7% | ||
| Q2 24 | -2.1% | 12.1% | ||
| Q1 24 | -0.4% | 12.4% |
| Q4 25 | — | $-0.78 | ||
| Q3 25 | — | $0.61 | ||
| Q2 25 | — | $0.56 | ||
| Q1 25 | — | $0.33 | ||
| Q4 24 | — | $0.42 | ||
| Q3 24 | — | $1.38 | ||
| Q2 24 | — | $0.75 | ||
| Q1 24 | — | $0.78 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $173.7M | $574.0M |
| Total DebtLower is stronger | $35.0M | $8.6B |
| Stockholders' EquityBook value | $126.7M | $752.0M |
| Total Assets | $1.3B | $12.9B |
| Debt / EquityLower = less leverage | 0.28× | 11.49× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $173.7M | $574.0M | ||
| Q3 25 | $171.7M | $672.0M | ||
| Q2 25 | $171.4M | $599.0M | ||
| Q1 25 | $136.9M | $547.0M | ||
| Q4 24 | $188.2M | $675.0M | ||
| Q3 24 | $148.2M | $763.0M | ||
| Q2 24 | $109.5M | $704.0M | ||
| Q1 24 | $111.7M | $575.0M |
| Q4 25 | $35.0M | $8.6B | ||
| Q3 25 | — | $8.8B | ||
| Q2 25 | — | $8.9B | ||
| Q1 25 | — | $9.0B | ||
| Q4 24 | — | $8.9B | ||
| Q3 24 | — | $8.7B | ||
| Q2 24 | — | $8.7B | ||
| Q1 24 | — | $8.7B |
| Q4 25 | $126.7M | $752.0M | ||
| Q3 25 | $306.1M | $906.0M | ||
| Q2 25 | $408.9M | $733.0M | ||
| Q1 25 | $500.3M | $542.0M | ||
| Q4 24 | $471.0M | $472.0M | ||
| Q3 24 | $574.9M | $493.0M | ||
| Q2 24 | $676.6M | $144.0M | ||
| Q1 24 | $689.3M | $48.0M |
| Q4 25 | $1.3B | $12.9B | ||
| Q3 25 | $1.6B | $13.6B | ||
| Q2 25 | $1.7B | $13.5B | ||
| Q1 25 | $1.9B | $13.2B | ||
| Q4 24 | $1.7B | $13.1B | ||
| Q3 24 | $2.1B | $12.8B | ||
| Q2 24 | $2.2B | $12.2B | ||
| Q1 24 | $2.3B | $11.9B |
| Q4 25 | 0.28× | 11.49× | ||
| Q3 25 | — | 9.74× | ||
| Q2 25 | — | 12.14× | ||
| Q1 25 | — | 16.52× | ||
| Q4 24 | — | 18.81× | ||
| Q3 24 | — | 17.75× | ||
| Q2 24 | — | 60.11× | ||
| Q1 24 | — | 181.54× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-20.5M | $141.0M |
| Free Cash FlowOCF − Capex | $-23.5M | $96.0M |
| FCF MarginFCF / Revenue | -1.5% | 6.4% |
| Capex IntensityCapex / Revenue | 0.2% | 3.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-119.0M | $538.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-20.5M | $141.0M | ||
| Q3 25 | $-18.2M | $264.0M | ||
| Q2 25 | $-35.1M | $220.0M | ||
| Q1 25 | $-32.0M | $75.0M | ||
| Q4 24 | $16.4M | $390.0M | ||
| Q3 24 | $-7.7M | $141.0M | ||
| Q2 24 | $-18.7M | $332.0M | ||
| Q1 24 | $-47.8M | $76.0M |
| Q4 25 | $-23.5M | $96.0M | ||
| Q3 25 | $-21.3M | $218.0M | ||
| Q2 25 | $-38.3M | $181.0M | ||
| Q1 25 | $-35.8M | $43.0M | ||
| Q4 24 | $13.2M | $335.0M | ||
| Q3 24 | $-11.2M | $99.0M | ||
| Q2 24 | $-22.0M | $300.0M | ||
| Q1 24 | $-50.9M | $30.0M |
| Q4 25 | -1.5% | 6.4% | ||
| Q3 25 | -1.5% | 13.6% | ||
| Q2 25 | -2.7% | 11.4% | ||
| Q1 25 | -2.3% | 2.8% | ||
| Q4 24 | 0.9% | 21.0% | ||
| Q3 24 | -0.8% | 6.3% | ||
| Q2 24 | -1.5% | 18.7% | ||
| Q1 24 | -3.2% | 1.8% |
| Q4 25 | 0.2% | 3.0% | ||
| Q3 25 | 0.2% | 2.9% | ||
| Q2 25 | 0.2% | 2.4% | ||
| Q1 25 | 0.3% | 2.1% | ||
| Q4 24 | 0.2% | 3.5% | ||
| Q3 24 | 0.2% | 2.7% | ||
| Q2 24 | 0.2% | 2.0% | ||
| Q1 24 | 0.2% | 2.8% |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.65× | ||
| Q2 25 | — | 1.52× | ||
| Q1 25 | -2.64× | 0.86× | ||
| Q4 24 | — | 3.58× | ||
| Q3 24 | — | 0.39× | ||
| Q2 24 | — | 1.70× | ||
| Q1 24 | — | 0.38× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AGL
| Medical Services | $1.6B | 100% |
| Other Operating | $2.5M | 0% |
OGN
Segment breakdown not available.
